Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750256 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects
A Phase 1 study of Anaemia, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00750256: Completed Phase 1 study of Anaemia, sponsored by GlaxoSmithKline.
NCT00750256 is a Phase 1 study of Anaemia that has completed, run by GlaxoSmithKline. The registered enrollment target is 36 participants, below the 64-participant average among 3 other Anaemia trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00750256, a Phase 1 study of Anaemia, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects
Conditions Studied
Interventions
- DRUG GSK1278863A
Study Locations (1)
Indiana
- GSK Investigational Site - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-07-07 |
| Est. Completion | 2008-12-12 |
| Phase | Phase 1 |
What the finished NCT00750256 record still lists
NCT00750256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 64-participant average among 3 other Anaemia trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Anaemia appearing as the primary indexed condition, and to 1 intervention - of which GSK1278863A is the first listed.
NCT00750256 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT00750256 about?
NCT00750256 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects". A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects
What is the current status of trial NCT00750256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-07-07. Estimated completion is 2008-12-12.
What conditions does trial NCT00750256 study?
This clinical trial studies the following conditions: Anaemia.
What interventions are being tested in trial NCT00750256?
The interventions under investigation include: GSK1278863A (DRUG).
Who is sponsoring clinical trial NCT00750256?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00750256 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
COMPLETED · Phase 1
-
Daprodustat Hepatic Impairment Study
COMPLETED · Phase 1
-
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI